• Home
  •  / U.S. Stem Cell

U.S. Stem Cell

OverviewSuggest Edit

U.S. Stem Cell is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's lead product candidate is MyoCell, an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients.

TypePublic
HQSunrise, FL, USMap
Websiteus-stemcell.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)10
Revenue (FY, 2018)$6.7 M(+22%)
Share Price (Jan 2021)$0 (+22%)
Cybersecurity ratingAMore

Key People/Management at U.S. Stem Cell

William P. Murphy

William P. Murphy

Chairman of the Board
Mike Tomás

Mike Tomás

President & CEO
Mark P Borman

Mark P Borman

CFO and Board Member
Show more

U.S. Stem Cell Office Locations

U.S. Stem Cell has an office in Sunrise
Sunrise, FL, US (HQ)
13794 NW 4th St #212
Sunrise, FL, US
1560 Sawgrass Corporate Pkwy 4th floor
Show all (2)

U.S. Stem Cell Financials and Metrics

U.S. Stem Cell Revenue

Embed Graph
View revenue for all periods
U.S. Stem Cell's revenue was reported to be $6.70 m in FY, 2018
USD

Revenue (Q3, 2019)

156.6k

Gross profit (Q3, 2019)

19.2k

Gross profit margin (Q3, 2019), %

12.3%

Net income (Q3, 2019)

(1.6m)

EBIT (Q3, 2019)

(1.6m)

Market capitalization (25-Jan-2021)

16.0m

Closing stock price (25-Jan-2021)

0.0

Cash (30-Sept-2019)

78.1k

EV

17.4m
U.S. Stem Cell's current market capitalization is $16 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

17.5k61.1k96.1k2.1m2.2m3.1m5.5m6.7m

Revenue growth, %

2040%7%41%

Cost of goods sold

694.01.1k30.8k844.9k973.0k972.0k1.9m2.1m

Gross profit

16.8k60.0k65.3k1.2m1.2m2.1m3.6m4.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

3.5k3.5k40.5k2.7k4.1k4.2k20.1k322.6k497.0k579.5k489.6k565.3k557.6k710.9k678.2k729.8k1.2m1.4m1.5m1.7m1.8m1.5m1.3m1.3m156.6k

Cost of goods sold

139.0139.0417.094.4k107.1k523.2k247.6k223.6k243.9k154.4k235.4k332.5k344.6k400.6k482.9k503.8k567.2k544.4k522.1k506.0k137.4k

Gross profit

3.4k3.4k40.1k228.1k389.9k56.3k241.9k341.7k313.7k556.6k442.9k397.3k810.4k985.3k1.0m1.2m1.3m959.5k786.7k792.0k19.2k

Gross profit Margin, %

96%96%99%71%78%10%49%60%56%78%65%54%70%71%68%71%69%64%60%61%12%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

36.8k46.2k36.7k58.4k270.7k986.8k1.4m

Accounts Receivable

3.5k1.3k19.9k95.4k35.0k16.0k43.0k18.0k

Prepaid Expenses

49.8k41.5k784.09.3k4.8k3.1k38.1k

Inventories

63.7k63.0k17.4k42.2k70.4k93.2k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

34.2k2.8k69.9k35.2k4.8k239.0k172.8k6.7k219.0k91.2k46.6k71.0k93.5k65.7k275.4k130.8k246.0k619.1k929.7k956.6k1.7m1.7m1.4m749.4k587.5k78.1k

Accounts Receivable

304.01.1k1.7k220.08.9k48.8k105.6k153.9k78.5k98.5k93.8k48.8k41.6k33.9k59.9k33.2k115.0k75.9k47.4k32.5k64.2k12.2k20.2k

Prepaid Expenses

86.6k99.0k88.4k56.1k71.0k79.4k3.1k1.7k4.0k26.2k258.01.8k9.2k28.1k38.1k38.1k38.1k38.1k38.1k

Inventories

64.3k64.1k63.3k63.3k63.3k30.5k33.7k40.4k41.0k38.0k59.0k76.7k66.1k72.6k70.9k43.7k46.4k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(4.7m)(4.0m)(3.1m)(2.3m)(1.6m)(2.1m)(3.5m)(2.2m)

Depreciation and Amortization

32.0k14.6k2.2k4.5k5.3k5.8k178.7k207.1k

Inventories

89.9k749.063.0k(17.4k)(24.8k)(28.1k)(22.9k)

Accounts Payable

301.1k324.3k(59.1k)858.4k434.5k10.5k469.2k426.3k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(2.5m)(3.7m)(946.9k)(1.7m)(2.8m)(518.9k)(1.3m)(2.4m)677.4k226.0k(1.2m)(1.0m)(161.6k)(283.0k)(363.3k)(716.2k)(2.4m)(2.5m)(2.9m)(3.8m)(139.2k)(1.4m)(1.7m)(673.2k)(1.5m)(3.2m)

Depreciation and Amortization

19.0k26.7k4.3k8.2k11.6k769.01.3k1.3k863.02.0k3.7k1.3k2.6k3.9k1.2k2.4k3.9k18.8k72.1k125.0k52.2k103.8k155.5k51.7k103.3k155.0k

Inventories

416.044.9k417.063.0k63.0k63.0k(13.1k)(16.3k)(23.0k)1.2k4.2k(16.8k)(6.3k)4.3k(2.3k)22.3k49.5k46.9k

Accounts Payable

369.7k268.0k254.2k222.6k272.6k(12.5k)(71.1k)(76.2k)172.8k255.4k628.7k114.5k243.0k324.0k(62.9k)13.8k78.5k205.5k305.1k519.4k188.2k204.5k332.6k123.9k195.9k269.1k
show all
USDQ2, 2011

Debt/Assets

1.3 x
Show all financial metrics

U.S. Stem Cell Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

Learn more about our premium products
SecurityScorecard logo

U.S. Stem Cell Online and Social Media Presence

U.S. Stem Cell's Trends

Embed Graph

U.S. Stem Cell News and Updates

December 06, 2018

USRM announces U.S. Stem Cell Clinic Expansion of Products and Services

SUNRISE, Fla., Dec. 6, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc., a leader in regenerative medicine products and services, today announced its three partially owned Florida-based clinics have expanded their menu of services to help meet the growing market demand and patient needs for...

U.S. Stem Cell Blogs

January 19, 2021

USRM Oral Argument in Appeal from FDA Enforcement Action

SUNRISE, FL – Jan 19, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce […]
September 30, 2020

U.S. Stem Cell Confirms Date for Appeals Court Oral Arguments

SUNRISE, FL – Sep. 30, 2020 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce […]
March 18, 2020

CEO Blog: A Summary of Recent Events

Dear Shareholders and Friends, Thank you for your continued interest and support in U.S. Stem Cell, Inc.  In an effort to keep you updated on matters related to the Company, […]
August 09, 2019

Corrected: USRM Posts Earnings for Second Quarter 2019

SUNRISE, FL – August 7, 2019 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today […]
August 07, 2019

USRM Posts Earnings for Second Quarter 2019

SUNRISE, FL – August 7, 2019 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today […]
May 07, 2019

USRM Posts Financial Results for First Quarter 2019

SUNRISE, FL – May 7, 2019 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today […]
Show more

 U.S. Stem Cell Frequently Asked Questions

  • Who are U.S. Stem Cell key executives?

    U.S. Stem Cell's key executives are William P. Murphy, Mike Tomás and Mark P Borman.

  • How many employees does U.S. Stem Cell have?

    U.S. Stem Cell has 10 employees.

  • What is U.S. Stem Cell revenue?

    Latest U.S. Stem Cell annual revenue is $6.7 m.

  • What is U.S. Stem Cell revenue per employee?

    Latest U.S. Stem Cell revenue per employee is $670.1 k.

  • Who are U.S. Stem Cell competitors?

    Competitors of U.S. Stem Cell include Enanta Pharmaceuticals, Immunic and Endologix.

  • Where is U.S. Stem Cell headquarters?

    U.S. Stem Cell headquarters is located at 13794 NW 4th St #212, Sunrise.

  • Where are U.S. Stem Cell offices?

    U.S. Stem Cell has an office in Sunrise.

  • How many offices does U.S. Stem Cell have?

    U.S. Stem Cell has 2 offices.